

FAX

GlaxoSmithKline

To Examiner Alan Rotman (Art Unit 1625)

Company USPTO

Fax 703-308-7922

From Valerie L. Phillips

Tel 919-483-8223 Fax 919-483-5730

E-mail Vlp47157@gsk.com

Date July 9, 2003 Pages including cover 4

Subject Supplemental Response After Final

Glaxo Wellcome Inc.
PO Box 13398
Five Moore Drive
Research Triangle Park
North Carolina 27709
Tel: 919 483 2100
www.gsk.com

Serial No.: 09/830,836

Filing Date: May 1, 2001

Applicant: Campbell et al.

Title: Pyrazolopyridine Derivatives as Selective COX-2 Inhibitors

Attached:

Certificate of transmission via facsimile
Supplemental Response After Final

Thank you,
Valerie Phillips

Certificate of Transmission by Facsimile (37 CFR 1.8)

I hereby certify that this Response to Office Action is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. 703-872-9306) on July 9, 2003.

Valerie L. Phillips
Valerie L. Phillips

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

*Please
enter
ADR*

PG3602USW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

'20
VC3
7-93

In re Application:

I. Campbell et al.,

Serial No.: 09/830,836

Examiner: B. Robinson

Filing Date: 1 May 2001

Art Unit: 1625

For: PYRAZOLOPYRIDINE DERIVATIVES AS SELECTIVE COX-2 INHIBITORS

Assistant Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL RESPONSE AFTER FINAL

Sir:

Further to the Office Action mailed 27 December 2002, the response filed 25 February 2003, the Interview with Examiner Alan Rotman on 8 July 2003 and the Advisory Action faxed to Applicants on 8 July 2003, please reconsider the instant application in view of the following remarks.

Remarks

Currently Claims 1-10, 14, 17-23 and 25-35 are pending.

The Final Rejection indicates that claims 1-10, 14, 17-18, 29 and 35 are allowed, claims 26-28 are rejected and claims 19-23 and 30-34 are withdrawn as directed toward non-elected species. The Final rejection fails to specify the status of pending claim 25, there is no rejection on the record for this claim and it was not withdrawn.

The Advisory Action indicates that claims 1-9, 14, 18, 29 and 35 are allowed, claims 26-28 are rejected and claims 19-23 and 30-34 are withdrawn and the Action fails to specify the status of claims 10, 17 and 25.